A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Adegramotide/nelatimotide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 20 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Apr 2019.
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.